Resolvin D1 shows osseous-protection via RANK reduction on monocytes during orthodontic tooth movement

Abstract

The study aimed to investigate the role of RvD1 in acute and prolonged sterile inflammation and bone remodeling. A mouse model of sterile inflammation that involves bone resorption was used to examine endogenous RvD1 kinetics during inflammation. Application of exogenous RvD1 significantly inhibited bone remodeling via osteoclast reduction, alongside an anti-inflammatory secretome shift, increased macrophages recruitment and reduction of T-cytotoxic cells. In vitro and in vivo, RvD1 led to significant reduction in RANK expression which reduce osteoclastogenesis in a dose-dependent manner. Taken together, the data shows a dual role for RvD1, as a potent immunoresolvent agent alongside an osteoresolvent role, showing a potential therapeutic agent in bone resorption associated inflammatory conditions.

Resolvin D1 improves allograft osteointegration and directly enhances osteoblasts differentiation

“…Healing), (d) second control group received allograft mixed with saline (allograft +single sham), (e) third control group received allograft mixed with saline + 3 gingival injections of saline at 4, 7, 10 days post ABR, to examine the effect of repetitive tissue injury on bone healing (rep-sham). The administration of RvD1 (15 ml, 0.51 mg/ml: 0.76 mg, per administration) or saline was performed as previously described (23).…”

Potential Clinical Applications of Pro-Resolving Lipids Mediators from Docosahexaenoic Acid

“…A relationship has been also observed with some (i) dental pathologies, such as inflammatory periodontal disease, which progresses rapidly and causes destruction of the supporting tissues of the teeth [157], with MaR1 improving the phagocytosis and destruction of periodontal pathogens [28]; likewise, orthodontic treatment produces a mechanical force that triggers an acute inflammatory process driven by cells and immune mediators [158], where, in the acute phase of inflammation, exogenous RvD1 favors resolution, whereas, in the prolonged phase, it suppresses osteoclast genesis [159]. (ii) Psoriasis would also be a disease that would benefit from DHA-derived SPMs, since PD1 decreases the symptoms of the disease including desquamation and erythema with a reduction in pro-inflammatory cytokine and chemokine formation, and improving the thickness of the skin [160].…”